Twice the size of the current facility, the new site will provide best-in-class logistical offerings to GEODIS’ customer base

AUCKLAND, NEW ZEALAND – Media OutReach – 3 August 2021 – GEODIS, a leading global transport and logistics operator, has announced a strategic move to a new facility at Auckland Airport, following strong and sustained growth in the New Zealand market. The 5700 sqm facility – with its prime location, advanced enterprise-grade systems, and extensive storage space – will offer GEODIS’ expanding client base the capacity needed to ensure seamless end-to-end supply chain support across both local and cross-border markets.

GEODIS in New Zealand gears up for major expansion with new facility at Auckland Airport 

The unprecedented surge in consumer demand brought about by the pandemic, has heightened the need for resilient supply chain strategies, particularly within the healthcare industry, with pharmaceutical companies forced to reinforce their logistical requirements. Keeping these needs in mind, GEODIS’ new site will feature specially designed temperature-controlled areas to facilitate the optimal storage of pharmaceutical products at +15-25 degrees as well as +4 degrees Celsius.

The growing demand will also be addressed by the site’s high productivity storage solution, which consists of two-metre wide aisle racking that affords 5,000 pallet locations. There is a tier one Warehouse Management System (WMS) that offers automated operating systems to support the thriving e-commerce fulfillment business. The purpose-built facility is located at one of Auckland’s most prominent industrial hubs at Auckland Airport with connections to the main arterial routes used for distribution. It will also house GEODIS’ international container freight station (CFS), contract logistics and last mile distribution set-up to enable full-service supply chain management under one roof.

“Significantly, this new facility is in harmony with our commitment to being a strong growth partner to our customers. As GEODIS continues to expand, we will also continue to enhance our infrastructure and processes to align our evolution with our customers’ development ambitions,” said Stuart Asplet, Sub-Regional Managing Director, Pacific & Regional Director Sea Freight, Asia Pacific. “The supply chain industry has certainly been disrupted by the pandemic, yet GEODIS’ passion to stay ahead of the curve has continuously pushed us to deliver industry-leading solutions that add value to our customers’ business goals. Our core belief to make a tangible impact on our clients’ goals, has allowed us to remain one of the fastest-growing logistics operators globally”.

The move further emphasises GEODIS’ focus on the APAC market and follows a series of investments and advancements made in the region over the past few months. The consolidation of the company’s operations from multiple sites to a single site will also boost efficiencies. The logistics provider has signed a long-term lease for the Auckland facility, encouraged by a healthy growth trajectory in the market.

“We’re confident that the facility at Auckland Airport will be a gamechanger for our customers. Features like the increased capacity, temperature control rooms, state-of-the-art technology, and advanced security measures ensure more precise and cost-efficient warehousing,” said Hugh Mackay, Managing Director, New Zealand. “This new site reflects the scale of things to come for our operations in New Zealand. Our laser sharp focus on providing a robust set of solutions and unmatched service to our customers holds the key to strengthening our presence in a competitive marketplace.”

The move will take place in October 2021 and is slated to amplify GEODIS’ offerings to more businesses including key verticals such as pharmaceuticals, retail, and fast-moving consumer goods (FMCG).

GEODIS – www.geodis.com

GEODIS is a top-rated, global supply chain operator recognized for its commitment to helping clients overcome their logistical constraints. GEODIS’ growth-focused offerings (Supply Chain Optimization, Freight Forwarding, Contract Logistics, Distribution & Express, and Road Transport) coupled with the company’s truly global reach thanks to a direct presence in 67 countries, and a global network spanning 120 countries, translates in top business rankings, #1 in France, #6 in Europe and #7 worldwide. In 2020, GEODIS accounted for over 41,000 employees globally and generated €8.4 billion in sales.

#GEODIS

Chery and Foresight, together with Guide Infrared, will collaborate on autonomous vehicles to develop advanced solutions based on Foresight’s technology

NESS ZIONA, ISRAEL – News Direct – 3 August 2021 – Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), an innovator in automotive vision systems, announced today the signing of a memorandum of understanding (MOU) for a multiphase business cooperation with Wuhu Chery Technology Co., LTD (Chery), a global Chinese vehicle manufacturer and Xuanyuan Idrive Technology Co. Ltd. (XY), a subsidiary of Wuhan Guide Infrared Co. (Guide Infrared) (Shenzhen stock code: 002414, market cap of approximately $10 billion), a leading Chinese developer and manufacturer of infrared thermal imaging systems.

During the first phase, Chery will test the QuadSight® vision prototype system for the purpose of evaluating Foresight’s technology and its potential further integration into advanced solutions for vehicles manufactured by Chery. Upon successful evaluation, the parties will negotiate a commercial agreement for the co-development of advanced solutions based on Foresight’s technology integrated with XY’s automotive sensors. The advanced solutions are designed for potential integration into semi- and fully autonomous vehicles manufactured by Chery.

As a part of the cooperation, the parties will consider establishing a joint venture in China, by themselves or with third parties. Furthermore, the parties are considering promoting and selling the advanced solutions in Greater China through the joint venture.

Additionally, to help accelerate innovation in the autonomous vehicles market and enable Foresight’s product expansion, Chery will consider a strategic investment in Foresight, in an amount and upon terms and conditions to be negotiated in the future.

“By signing this cooperation MOU with a leading automotive OEM, we continue our strategy to expand our presence in the Chinese automotive market. Our advanced 3D vision technologies combined with Guide Infrared’s thermal imaging capabilities potentially offer an accurate and reliable vision solution that can be integrated into Chery’s semi- and fully autonomous vehicles to enhance their current safety systems,” said Haim Siboni, CEO of Foresight. “I believe that this vote of confidence from another vehicle manufacturer, along with a potential strategic investment, may open the door for additional opportunities, worldwide and specifically in the Asian automotive market.”

About Wuhu Chery Technology

Chery is a Chinese automotive brand with global influence. It has a powerful R&D strength of engine, gearbox, chassis and other core technologies among Chinese automobile brands, and has established a global automobile R&D team of more than 5,500 people. Meanwhile, Chery is also among the first Chinese automobile company to export vehicles, complete knock-down parts, engines and vehicle manufacturing technology and equipment to the world. Up until now, Chery has exported its vehicles to more than 80 countries and regions, with nearly 9.4 million users worldwide, ranking first in the number of passenger cars exported from China for 18 consecutive years.

About Wuhan Guide Infrared

Wuhan Guide Infrared Co., Ltd. (Shenzhen stock code: 002414), founded in 1999, is engaged in manufacturing infrared detectors and cameras, comprehensive electro-optical systems and large-scale defense systems. Guide Infrared provides infrared solutions, ranging from infrared devices up to complete systems. The Company has established a state-of-the-art mass production facility located at China Optics Valley in Wuhan with more than 2,600 employees.

Guide Infrared develops and manufactures infrared solutions for national defense security, protection systems, diagnostic tools, smart home, internet of things, intelligent terminals, machine vision systems, automotive industry, unmanned planes and other applications.

About Foresight

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) is a technology company developing smart multi-spectral vision software solutions and cellular-based applications. Through the Company’s wholly owned subsidiaries, Foresight Automotive Ltd. and Eye-Net Mobile Ltd., Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of-sight” accident-prevention solutions.

Foresight’s vision solutions include modules of automatic calibration, sensor fusion and dense 3D point cloud that can be applied to diverse markets such as automotive, defense, autonomous vehicles and heavy industrial equipment. Eye-Net Mobile’s cellular-based solution suite provides real-time pre-collision alerts to enhance road safety and situational awareness for all road users in the urban mobility environment by incorporating cutting-edge AI technology and advanced analytics.

For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit www.foresightauto.com, follow @ForesightAuto1 on Twitter, or join Foresight Automotive on LinkedIn.

#Foresight

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Foresight is using forward-looking statements in this press release when it discusses that Chery will test the QuadSight® vision prototype system, that, subject to certain conditions, Chery and Foresight will negotiate a commercial agreement for the co-development of advanced solutions, that the parties will consider establishing a joint venture in China, that Chery may consider a strategic investment in Foresight, and that MOU and a potential strategic investment by Chery in Foresight may bring additional opportunities worldwide and specifically in the Asian automotive market for Foresight. Because such statements deal with future events and are based on Foresight’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Foresight could differ materially from those described in or implied by the statements in this press release.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Foresight’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 30, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, Foresight undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Foresight is not responsible for the contents of third-party websites.

NEW YORK, US and LONDON, UK – News Direct – 2 August 2021 – Symphony – the leading markets’ infrastructure and technology platform – will now offer the most complete and secure verified directory in the financial services industry as it has acquired the counterparty mapping platform StreetLinx. This acquisition adds over 200 institutional counterparties to the more than 1000 institutions already served by Symphony.

“As we accelerate from directory to identity solutions, Streetlinx brings Symphony a full spectrum of identity-verified investment professionals, including portfolio managers, traders, research analysts and sales teams that will enrich Symphony’s already established and active community of over half a million financial professionals. We are proud to continue to add value to our user community and the industry as a whole”, said Symphony CEO Brad Levy.

A secure, enriched and up to date verified directory is a key tool in markets as it increases efficiency and reduces risk across the board. Integrations between the Symphony and StreetLinx platforms are already being deployed, enabling enhanced directory information, entitlement based connections and content distribution across trusted counterparties. The combined solution brings standardization and entitlements to allow professionals to seamlessly connect with the right counterparty, person or platform.

StreetLinx CEO Gary Godshaw explained: “We founded StreetLinx to modernize the exchange of organizational data and drive better connectivity between counterparties. While we knew the pain points well, it was really our clients who have led and shaped the solution since day one. Joining Symphony is a perfect fit for StreetLinx’s clients and for us as a team. Our combined offering will expand the scope of applications and increase the breadth of use cases for our users from front to back office. We are thrilled to be joining such a strong brand and culture. This deal simply formalizes what has felt like a partnership from the start.”

Levy has previously shared that Symphony would buy, partner with, or acquire strategic assets for the company and the industry. Symphony acquired the trader voice and electronic communication company Cloud 9 Technologies in June, positioning the company to take the lead in front office communications with new services and solutions combining trader voice with natural language processing (NLP) and automation. The company also announced in July it had chosen Google Cloud as its primary cloud provider and would be migrating its platform in the coming year.

Marlin & Associates and Goodwin Procter LLP were financial and legal advisers, respectively, to Symphony, while Broadhaven Capital Partners and Goodwin Procter LLP were financial and legal advisers, respectively, to Streetlinx in this transaction. Financial details of this transaction have not been disclosed.

About Symphony

Symphony is the most secure and compliant markets’ infrastructure and technology platform, where solutions are built or integrated to standardize, automate and innovate financial services workflows. It is a vibrant community of over half a million financial professionals with a trusted directory and serves over 1000 institutions. Symphony is powering over 2,000 community built applications and bots. For more information, visit www.symphony.com.

About Streetlinx

StreetLinx, the preeminent financial services counterparty mapping platform, is a marketplace for the exchange of organizational data with trusted third parties. The firm standardizes internal directories and provides entitlement controls for sharing bilaterally between counterparties. 130+ buy-side firms and 50+ dealers have joined the platform since its launch in 2019.

#Symphony #StreetLinx

HANOI, VIETNAM – Media OutReach – 2 August 2021 – Supported by the Vietnamese Government and Health Ministry, Vingroup (HOSE: VIC) and Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced a contract regarding a collaboration to establish a manufacturing facility in Vietnam for the manufacture of Arcturus’ mRNA COVID-19 vaccine candidate for sales and use in Vietnam.  With a planned capacity of up to 200 million doses per year, Vingroup is expected to produce its first batches of the COVID-19 vaccine in early 2022.  

Arcturus Therapeutics is a leading clinical stage company focused on messenger RNA (mRNA) medicines – one of the most advanced medicinal technologies in the world. Under the terms of the arrangement, VinBioCare – a member of Vingroup – will, with consultation from Arcturus, build out a manufacturing facility in Vietnam; and Arcturus will provide to VinBioCare access to proprietary technologies and processes for the final drug product manufacturing of Arcturus’ investigational COVID-19 vaccine. Arcturus will provide VinBioCare with an exclusive license to manufacture the vaccine at the Vietnam facility solely for sales and use in Vietnam.

VinBioCare’s vaccine factory is located inside VinSmart’s electronic equipment complex in Hoa Lac Hi-tech Park (Thach That District, Hanoi), with a total estimated investment of 200 million USD and capacity of 200 million doses per year.

Currently, VinBioCare has already signed equipment procurement contracts for this factory. As planned, all equipment will be transported to Vietnam via special flights to ensure timely arrivals in September 2021. So far, construction has also completed while the installation of equipment is expected to be finalized in November 2021.

To ensure the highest production standards, VinBioCare has cooperated with Rieckermann (Germany) – one of the leading machinery & industrial solution providers in the pharmaceuticals industry – to promptly carry out the construction of the 8,807m2 factory following GMP requirements.

“In response to the Vietnamese Government’s guideline on COVID-19 vaccine supply for Vietnam in the time of limited source of supply and outbreaks, Vingroup has proactively looked for prestigious international partners for cooperation and conducted procurement and construction of the vaccine factory as quickly as possible.” – said Vingroup’s Vice Chairwoman Le Thi Thu Thuy. “Vingroup really expects to make a modest contribution to the fight against COVID-19 in Vietnam and the world, so that all people can live a normal life again.”

Arcturus investigational COVID-19 vaccines utilizes Arcturus’ lipid-mediated delivery system called LUNAR® delivery system, and Arcturus’ self-amplifying mRNA technology, known as STARR™. This self-amplifying technology is designed to promote a prolonged immune response using a lower dose compared to conventional mRNA vaccines. mRNA vaccine technology enables rapid modification of the antigen that could help to accelerate the development of vaccines against SARS-CoV-2 variants.

Notably, the vaccine candidate, called VBC-COV19-154 domestically, can be made in a lyophilized powder form which is favorable for packaging, storage, transport, distribution and supply.

As planned, VinBioCare will coordinate with the Vietnamese Health Ministry’s Administration of Science Technology & Training to carry out Phase 3 clinical trials of VBC-COV19-154 vaccine on 20,000 people in August 2021.

In December 2021, VinBioCare plan to complete and submit procedures to the Health Ministry to ask for approval for VBC-COV19-154 vaccine for emergency use in Vietnam.

Once produced domestically, VBC-COV19-154 is expected to be cheaper than products of similar segment in the market. Notably, VinBioCare will provide COVID-19 vaccine at break-even price excluding investment costs in Vietnam during the time of pandemic.

About Arcturus

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, and Cystic Fibrosis along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (222 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

About Vingroup and VinBioCare

As the largest private conglomerate in Vietnam and one of the largest in Asia, Vingroup is currently doing business in three core sectors namely technology, industry and services. In all sectors it has participated in, Vingroup is always a pioneer that leads market trends and creates world-class products and services of Vietnam. Find out more at: https://www.vingroup.net/en

VinBioCare Biotechnology JSC (a member company of Vingroup) is a Vietnamese business working on vaccine and biological products. VinBioCare’s major resources are transferred from Viet A Corporation – a specialist in biotechnology with substantial market shares in Vietnam. The corporation was also Vietnam’s first producer of real-time PCR test kit for SARS-CoV-2 and is currently the supplier to about 90% of health care centers throughout the country.

#vingroup #VinBioCare #Arcturus

A Wide Spectrum of Medical Specialties under One Roof to Support Expansion and Meet Demand for One-stop Quality Medical Services

HONG KONG SAR – Media OutReach – 2 August 2021 –  Hong Kong Medical Consultants Holdings Limited (“Hong Kong Medical Consultants”, “HKMC” or the “Group”), a leading multi-specialty medical services group in Hong Kong, announced today the grand opening of the HKMC Integrated Medical Centre on the 9^th Floor of Central Building, Central, Hong Kong.

HKMC Integrated Medical Centre provides a wide range of 11 medical specialties.

Established in 2013, HKMC is a multi-disciplinary private medical services group, operating under a doctor-led management team and chaired by its founder Dr. Kenneth Tsang. The Group comprises specialist doctors and allied healthcare professionals with extensive clinical experience in their respective areas of expertise.

With a GFA of approximately 16,200 sq. ft. on the entire 9^th Floor of Central Building, the HKMC Integrated Medical Centre has been running smoothly since its commencement of operations in June 2021. The new Integrated Medical Centre is supported by a team of 15 specialist doctors spanning 11 medical specialties (Respiratory Medicine, Cardiology, Neurology, Geriatric Medicine, Nephrology, Paediatrics, Oncology, Psychiatry, Gastroenterology & Hepatology, Endocrinology, Diabetes & Metabolism and Rheumatology).

In October 2019, the Group also acquired Hong Kong Imaging and Diagnostic Centre Limited, which has two imaging and diagnoses centres and one laboratory located in Central, thereby providing the Group’s  diagnostic services with in-house imaging and other diagnostic facilities.

Dental services have been newly introduced in May 2021, expanding the Group’s capabilities in meeting the rising demand for private specialty services in Hong Kong, with an estimated CAGR of revenue of 5.8% increasing from HK$29.7 billion in 2020 to HK$37.3 billion in 2024[1].

HKMC will continue to recruit talented medical practitioners in Hong Kong by taking advantage of the trend of consolidation of smaller medical practices in Hong Kong.  A number of key intitaitves will be spearheaded to provide a wider variety of specialist medical services, including:

• the addition of dermatology specialist service by setting up a new dermatology centre. It will lead to our further growth because there is a strong demand for dermatology services for both medical and aesthetic purposes;
• the extension of oncology specialist services by setting up a new oncology centre;
• HKMC’s purchase of the 6^th floor of Euro Trade Centre in Central (GFA of approximately 5,200 sq. ft.) in March 2021, and the Group will establish a comprehensive diagnostic centre with CT, MRI, ultrasound and other related imaging and diagnostic facilities on the same floor;
• the recently introduced medical concierge services of HKMC will assist the promotion of new businesses through the initiation of health check programmes; and
• the licensed wholesale pharmacy where HKMC can store and distribute medicine to its Medical Centres as well as to other third-party private medical practitioners on a wholesale basis.

About Hong Kong Medical Consultants (HKMC)

Established in 2013, HKMC is a multi-specialty private medical services group in Hong Kong, comprising specialist doctors and allied healthcare professionals with extensive clinical experience in their respective areas. HKMC provides a wide range of specialist medical services, complemented by various allied health and medical management services under two brands (namely “Hong Kong Medical Consultants” and “Hong Kong Imaging and Diagnostic Centre”). Currently, the Group covers 11 medical specialties, including Respiratory Medicine, Cardiology, Neurology, Geriatric Medicine, Nephrology, Paediatrics, Oncology, Psychiatry, Gastroenterology & Hepatology, Endocrinology, Diabetes & Metabolism and Rheumatology.

Website: www.hkmedicalconsultants.com

#HongKongMedicalConsultants #HKMC

HONG KONG SAR & SHANGHAI, CHINA – Media OutReach – 2 August 2021 – Hang Lung Properties has been awarded the “2021 Corporate Social Responsibility Model Award” at the 10^th China Finance Summit, recognizing its long-term commitment to corporate social responsibility and promoting community investment and sustainable development for the community – a tangible expression of the company’s motto, We Do It Well.  

Hang Lung Properties has been awarded the “2021 Corporate Social Responsibility Model Award” at the 10th China Finance Summit, recognizing its long-term commitment to corporate social responsibility and promoting community investment – a tangible expression of the company’s motto, We Do It Well. 

Mr. Weber Lo, Chief Executive Officer of Hang Lung Properties, said, “As a leading real estate developer, Hang Lung pursues sustainable growth by connecting our customers and communities. Our 2030 sustainability goals and targets are an operational priority, helping us on our path become one of the most sustainable real estate companies in the world. An integral part of our corporate culture is the distilling of our concern for “caring about people” through all levels of the organization. In all our endeavors, from talent cultivation and employee wellbeing to environmental protection and community engagement, we are committed to creating shared value for all our stakeholders. To this end, we encourage our employees to be actively involved in volunteer activities, and continuously commit our resources to sustainable community investment initiatives.”

Hang Lung has always been committed to fulfilling its corporate social responsibilities and established the “Hang Lung As One Volunteer Team” in Hong Kong in 2012 to take the lead in community projects. In addition to Hong Kong, currently all 11 projects across the company’s Mainland portfolio encompassing Shanghai, Shenyang, Jinan, Wuxi, Tianjin, Dalian, Kunming, Wuhan, and Hangzhou, have formed teams of local volunteers with a focus on youth development and education, elderly services, and environment protection. Leveraging its corporate resources and the generous commitment of its staff, the company hopes to build an inclusive and diverse society. In the past year alone, Hang Lung As One received the support of close to 1,700 members, who participated in over 100 service programs, reaching over 20,000 beneficiaries and contributing over 13,000 service hours. To commemorate the company’s anniversary in a meaningful way, our volunteer teams consisting of staff and their family members, friends, and tenants, will join forces in a nation-wide volunteer activity every September.

Volunteerism is part of the Hang Lung corporate culture. By providing opportunities to serve, training, and due recognition, the company encourages staff, along with their family members and friends, to join volunteer programs to address social needs. The “2021 Corporate Social Responsibility Model Award” and the “2020 Public Welfare Practice Award” previously awarded at the 10^th China Charity Festival are an encouraging recognition of the company’s commitment and its people’s dedication to community investment.

The “2021 Corporate Social Responsibility Model Award” was presented by the China Finance Summit. Established in 2012, the China Finance Summit is one of the most influential events in China’s economic field and celebrates its 10^th edition this year. It covers a range of programs including talks, executive conversation, and a sharing section with more than 1,000 representatives from the business, politics, academia, and media sectors to explore the driving forces of China’s economic development.

About Hang Lung Properties

Hang Lung Properties Limited (stock code: 00101) creates compelling spaces that enrich lives. Headquartered in Hong Kong, Hang Lung Properties develops and manages a diversified portfolio of world-class properties in Hong Kong and the nine Mainland cities of Shanghai, Shenyang, Jinan, Wuxi, Tianjin, Dalian, Kunming, Wuhan and Hangzhou. With its luxury positioning under the “66” brand, the company’s Mainland portfolio has established its leading position as the “Pulse of the City”. Hang Lung Properties is recognized for leading the way in enhanced sustainability initiatives in real estate as it pursues sustainable growth by connecting customers and communities.

At Hang Lung Properties – We Do It Well.

For more information, please visit www.hanglung.com.

#HangLungProperties